IRON (III) HYDROXIDE POLYMALTOSE COMPLEX, A NEW-GENERATION DRUG, FOR THE TREATMENT OF IRON-DEFICIENCY ANEMIA
- Authors: Milovanova L.1, Milovanov Y.1, Kozlovskaya L.1
-
Affiliations:
- I.M. Sechenov First Moscow State Medical University
- Issue: Vol 24, No 1 (2013)
- Pages: 54-57
- Section: Articles
- URL: https://journals.eco-vector.com/0236-3054/article/view/115595
- ID: 115595
Cite item
Open Access
Access granted
Abstract
The paper gives the results of preclinical and clinical studies evaluating the efficacy and safety of iron (III) polymaltose complex in the treatment of iron deficiency with and without anemia being developed. The adverse reactions of the complex were generally the same or less pronounced than those of iron salts. The complex may be used for the treatment and prevention of iron-deficiency anemia in all patient groups.
Full Text
About the authors
L. Milovanova
I.M. Sechenov First Moscow State Medical University
Yu. Milovanov
I.M. Sechenov First Moscow State Medical University
Email: yuriymilovanov@mail.ru
L. Kozlovskaya
I.M. Sechenov First Moscow State Medical University
References
- Kidney Discase. Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO Clinical Practice Guideline for Anemia in Cronic Kidney Disease // Kidneyinter. - 2012; 2 (Suppl.): 114-64.
- Милованов Ю.С. Нефропротективная стратегия у больных ХБП на додиализном этапе. Lambert Academic Publishin. Germany. - 2011; 157 с.
- Николаев А.Ю., Милованов Ю.С. Лечение почечной недостаточности. 2-е изд / М.: МИА, 2011; 585 с.
- Soboleva M. Iron-deficiency anaemia children and breastfeeding mothers and its treatment and prophylaxis with Maltofer and Maltofer-Fol // Педиатрия. -2001; 6: 27-32.
- Soboleva M. Iron deficiency anaemia in infants: diagnosis and present-day therapy // Вопросы гематологии и иммунопатологии в педиатрии. - 2003; 2: 32-7.
- Cook J., Skikne B., Baynes R. Iron deficiency: the global perspective. Progress in Iron Research // Adv. Exp. Med. Biol. - 1994; 356: 219-28.
- Brock C., Curry H., Hanna C. et al. Adverse effects of iron supplementation: a comparative trial of a wax-matrix iron preparation and conventional ferrous sulfate tablets // Clin. Ther. - 1985; 7: 568-73.
- Anderson A. Iron poisoning in children // Curr. Opin. Ped. - 1994; 6: 289-94.
- Litovitz T., Klein-Schwartz W., Rodgers G. et al. Annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System // Am. J. Emerg. Med. - 2002; 20: 391-452.
- Hutchinson C., Al-Ashgar W., Liu D. et al. Oral ferrous sulphate leads to a marked increase in pro-oxidant nontransferrin-bound iron // Eur. J. Clin. Invest. -2004; 34: 782-4.
- Geisser P., Baer M., Schaub E. Structure/histotoxicity relationship of parenteral iron preparations // Arzneimittel-Forschung (Drug. Res.). - 1992; 42: 1439-52.
- Geisser P., Muller A. Iron pharmacokinetics after administration of ferrichydroxide-polymaltose complex in rats // Arzneimittel-Forschung (Drug. Res.). -1984; 34 (11): 1560-9.
- Geisser P. Iron Therapy, Oxidative Stress and Immunology. In: Chandra RK, ed. Nutrition and Immunology in the 21st Century. New Dehli (India). Ontario (Canada) / TSAR Health. - 2004; р. 53-65.
- Lundqvist H., Sjoberg F. Food interaction of oral uptake of iron. A clinical trial using 59Fe // Arzneimittel-Forschung (Drug. Res). - 2007; 57 (6a): 401-16.
- Funk F., Canclini C., Geisser P. Interactions between iron (III)-hydroxide polymaltose complex and commonly used medications. Laboratory studies in rats // Arzneimittel-Forschung (Drug. Res.). - 2007; 57 (6a): 370-5.
- Jacobs P., Johnson G., Wood L. Oral iron therapy in human subjects, comparative absorption between ferrous salts and iron polymaltose // J. Med. -1984; 15: 367-77.
- Tuomainen T., Nyyssonen K., Porkkala-Sarataho E. et al. Oral supplementation with ferrous sulphate but not with non-ionic iron polymaltose complex increases the susceptibility of plasma lipoproteins to oxidation // Nutr. Res. - 1999; 19: 1121-32.
- Langstaff R., Geisser P., Heil W. et al. Treatment of ironde-ficiency anaemia: a lower incidence of adverse effects with Ferrum Hausmann than ferrous sulphate // Brit. J. Clin. Res. - 1993; 4: 191-8.
- Jacobs P., Wood L., Bird A. Better tolerance of iron polymaltose complex compared with ferrous sulphate in treatment of anaemia // Hematology. - 2000; 5: 77-83.
- Sas G., Nemesanszky E., Brauer H. et al. On the therapeutic effects of trivalent and divalent iron in iron deficiency anaemia // Arzneimittel-Forschung. (Drug. Res.). - 1984; 34: 1575-9.
- Schmidt B., Morais M., Fisberg M. et al. Comparacao terapeutica entre o sulfato ferroso e o ferro trivalente em forma de complexo dehidr6xido ferrico polimaltosado na deficiencia organica de ferro // Folha Med. - 1985; 90: 25-9.
- Милованов Ю.С., Лысенко Л.В., Милованова С.Ю. и др. Препараты эритропоэтина и железа в лечении анемии у больных хронической болезнью почек на преддиализных стадиях и при проведении программного гемодиализа // Медицинский совет. - 2009; 1: 13-8.
- Милованов Ю.С., Козловская Л.В., Милованова Л.Ю. Анемия у больных с хронической болезнью почек: принципы терапии // Качество жизни. Медицина. - 2006; 4 (15): 90-5.
- Geisser P. Iron therapy with special emphasis on oxidative stress. Rorschach (Switzerland): Lopfe-Benz AG, 1998.
- Tuomainen T., Nyyssonen K., Porkkala-Sarataho E. et al. Oral supplementation with ferrous sulphate but not with non-ionic iron polymaltose complex increases the susceptibility of plasma lipoproteins to oxidation // Nutr. Res. - 1999; 19: 1121-32.
- Милованов Ю.С. Хроническая почечная недостаточность. В кн.: Рациональная фармакотерапия. Под ред. Н.А. Мухина, Л.В. Козловской, Е.М. Шилова / М.: Литтера. - 2006; 13: 585-601.
Supplementary files
